导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 2.63% | 1690/4764 |
| 近一周 | -2.28% | 4215/5455 |
| 近一月 | -5.17% | 2205/5409 |
| 近一季 | -8.42% | 2668/5227 |
| 近半年 | 1.37% | 1307/4921 |
| 近一年 | 6.27% | 1423/4391 |
| 近两年 | 50.24% | 1464/2946 |
| 近三年 | 31.88% | 997/2246 |
| 成立以来 | 242.63% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-2.71% 2876/4961 |
17.41% 1468/5312 |
- - |
- - |
| 2025 | 21.24% 2048/4813 |
2.42% 1381/3635 |
2.29% 1675/4076 |
13.65% 2975/4524 |
1.83% 1202/4813 |
| 2024 | 14.72% 1019/3463 |
4.23% 468/2808 |
-1.21% 984/3014 |
13.74% 2120/3129 |
-2.05% 1938/3463 |
| 2023 | -9.24% 1138/2656 |
3.79% 1126/2280 |
-3.15% 746/2385 |
-2.76% 742/2515 |
-7.15% 2074/2655 |
| 2022 | -19.60% 872/2207 |
-12.44% 609/1919 |
6.04% 782/2016 |
-14.14% 1029/2113 |
0.85% 1439/2208 |
| 2021 | -0.03% 734/1822 |
-0.64% 379/1255 |
7.21% 692/1330 |
-6.46% 932/1466 |
0.33% 1135/1822 |
| 2020 | 39.84% 322/1250 |
-7.49% 547/1028 |
15.83% 470/1067 |
14.49% 273/1164 |
13.98% 313/1184 |
| 2019 | 44.44% 171/1092 |
28.40% 312/754 |
1.36% 135/804 |
3.95% 225/850 |
6.76% 553/918 |
| 2018 | -22.55% 246/834 |
- - |
- - |
- - |
-13.19% 515/691 |
| 2017 | 27.33% 88/714 |
- - |
- - |
- - |
- - |
| 2016 | -3.50% 143/605 |
- - |
- - |
- - |
- - |
| 2015 | 19.64% 119/575 |
- - |
- - |
- - |
- - |
| 2014 | 64.15% 26/237 |
- - |
- - |
- - |
- - |
| 2013 | -7.57% 125/186 |
- - |
- - |
- - |
- - |
| 2012 | 10.57% 39/140 |
- - |
- - |
- - |
- - |
| 2011 | -18.96% 25/102 |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 港股医疗ETF | 1.4546 | 31.90% |
| 华富中证港股通创新药指数型发起式A | 1.1637 | 30.96% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.3128 | 30.52% |
| 中欧中证港股通创新药指数发起A | 1.6103 | 30.52% |
| 嘉实中证港股通创新药指数发起式C | 0.8566 | 30.50% |
| 中欧中证港股通创新药指数发起C | 1.4583 | 30.44% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8927 | 30.26% |
| 景顺长城中证港股通创新药ETF联接C | 1.4696 | 29.97% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8736 | 29.94% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8719 | 29.88% |
| 宏利沪深300指数A VS. 长安沪深300非周期A(740101) |